Brief: Essex Bio-Technology Updates On U.S. FDA First Phase 3 Clinical Trial Relating To Dry Eye Disease
July 19 (Reuters) - Essex Bio-Technology Ltd 1061.HK :
* UPDATES ON U.S. FDA FIRST PHASE 3 CLINICAL TRIAL RELATING
TO DRY
EYE DISEASE
* ESSEX BIO-INVESTMENT & MITOTECH DISCUSSING ON TAKING U.S.
FDA
PHASE 3 CLINICAL TRIAL OF PRODUCT TO SECOND PHASE 3 CLINICAL
TRIAL
* POSITIVE TOPLINE DATA ACHIEVED DURING FIRST P3 TRIAL
SHOWING
CLINICALLY RELEVANT SIGNS OF EFFICACY & SAFETY OF PRODUCT
Source text for Eikon: urn:newsml:reuters.com:*:nHKS63jV4m
Further company coverage: 1061.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share